Corona Virus Infection, Stomach Cancer
Conditions
Keywords
gastric surgery, COVID-19, SARS-COV-2, pandemic, stomach surgery, cancer surgery
Brief summary
The aim of this study is to analyze whether COVID-19 causes a delay in the diagnosis of gastric cancer patients particularly in the TNM staging of the tumor, or not and to compare the number of newly diagnosed patients with gastric cancer before and during the COVID-19 pandemic period.
Detailed description
The study included the patients diagnosed with gastric cancer during the period between March 1, 2020, and December 31, 2020, in the pandemic group at the Adana City Training and Research Hospital, Department of General Surgery, Divisions of Gastroenterological Surgery and Surgical Oncology. For the baseline group, patients diagnosed with gastric cancer between January 1, 2019, and December 31, 2019, was included in the same department. Clinical and pathological data of the patients were retrospectively collected from the hospital medical records. The following parameters were compared between the pandemic and baseline periods; age and gender distributions, mean monthly numbers of newly diagnosed patients, CEA and CEA-19.9 levels, the type of the surgery, the location of the tumor, the frequency of the patients receiving neoadjuvant treatment, American Society of Anesthesiologists (ASA) score, length of the hospital stay, clinical staging and pathologic TNM staging.
Interventions
PROCEDUREGastric cancer surgery
Appropriate gastric cancer surgery types for the convenient patients
Sponsors
Adana City Training and Research Hospital
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
Patients newly diagnosed with gastric cancer at specified intervals will be included in the study.
Exclusion criteria
* Having an additional second primary tumor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the mean monthly numbers of newly diagnosed gastric cancer patients between the groups | from March 1, 2020 to December 31, 2020 -from January 1, 2019 to December 31, 2019 | numbers of newly diagnosed gastric cancer |
| Comparison of the clinical staging and pathologic TNM staging of the patients | from March 1, 2020 to December 31, 2020 -from January 1, 2019 to December 31, 2019 | Clinical staging was determined based on the results of a physical exam, biopsy, and imaging tests including computed tomography (CT), PET CT, endoscopy and the endoscopic ultrasound. Surgical stage refers to the pathologic stage of the surgical specimen determined based on the American Joint Committee on Cancer (AJCC) TNM system. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the demographic data | from March 1, 2020 to December 31, 2020 -from January 1, 2019 to December 31, 2019 | age and gender distributions, mean monthly numbers of newly diagnosed patients, CEA and CEA-19.9 levels, the type of the surgery, the location of the tumor, the frequency of the patients receiving neoadjuvant treatment, American Society of Anesthesiologists (ASA) score, length of the hospital stay, |
Countries
Turkey (Türkiye)
Outcome results
None listed